Analysis of Apoaequorin as a Therapeutic Agent for Schizoprenia, Depression, and Cognitive Decline

The main goals of this research are to investigate the efficacy of acute apoaequorin [APO] to rescue cognitive and negative symptom deficits, alone, as well as an adjunct to atypical antipsychotic drugs [e.g. lurasidone, rivastigmine, SSRIs such as memantine, and curcumin in aged, and Alzheimers [5XFAD], and subchronic Phencyclidine [sc-PCP] mouse models. The objective is also to understand the efficacy of chronic APO in aged and 5xFAD mouse models. The goal is also to investigate the effect of acute and daily oral APO treatment to delay or prevent cognitive impairments in aged mice on working memory, episodic memory, and negative symptoms Since stress plays a crucial part in the normal functioning of memory and social interaction behaviors, we plan to determine the antidepressant action of APO in normal, and acute stressed mice using the forced swim test [FST]. We also intend to understand the effect of APO on obsessive-compulsive behavior [OCD] using marble burying behavior [MBB].